

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

May 5, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated May 5, 2017, titled Zydus receives final approval from the USFDA for Budesonide Capsules.

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for,

UPEN H. SHAH
COMPANY SECRETARY



Zydus receives final approval from the USFDA for Budesonide Capsules

Ahmedabad, India, 5 May 2017

Zydus Cadila has received the final approval from the USFDA to market Budesonide Capsules, 3 mg (Enteric Coated). The drug is a corticosteroid used for its anti-inflammatory action.

It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is \$ 285.8 million (*IMS MAT March 2017*).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
